Dr Reddys Laboratories (RDY) Total Non-Current Liabilities (2009 - 2026)
Dr Reddys Laboratories (RDY) posted quarterly Total Non-Current Liabilities of $334.0 million for Q1 2026, up 12.08% year-over-year from $298.0 million in Q1 2025, and up 12.08% quarter-over-quarter from $298.0 million in Q1 2025.
Dr Reddys Laboratories (RDY) Total Non-Current Liabilities (2009 - 2026) Analysis & Trends
Dr Reddys Laboratories' Total Non-Current Liabilities history runs 10 years deep, the most recent figure standing at $334.0 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities rose 12.08% year-over-year to $334.0 million; the TTM figure through Mar 2026 stood at $334.0 million (up 12.08% YoY), while the FY2026 annual figure was $334.0 million, up 12.08% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $334.0 million, up from $298.0 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $334.0 million in Q1 2026, with the low at $61.0 million in Q1 2023.
- The 5-year median for Total Non-Current Liabilities is $132.0 million (2024), against an average of $186.8 million.
- The sharpest annual moves came in 2023 and 2025: Total Non-Current Liabilities slumped 44.04% in 2023, then surged 125.76% in 2025.
- Dr Reddys Laboratories' Total Non-Current Liabilities stood at $109.0 million in 2022, then plunged by 44.04% to $61.0 million in 2023, then jumped by 116.39% to $132.0 million in 2024, then surged by 125.76% to $298.0 million in 2025, then gained by 12.08% to $334.0 million in 2026.
- Business Quant data shows RDY's Total Non-Current Liabilities at $334.0 million in Q1 2026, $298.0 million in Q1 2025, and $132.0 million in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.79 Bn | 30.11 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.69 Bn | 22.89 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.58 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 334.00 Mn |
| 10 | Alkermes | 8.15 Bn | 7.49 Bn | 397.90 Mn | 2.45 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 334.00 Mn |
| Mar 31, 2025 | 298.00 Mn |
| Mar 31, 2024 | 132.00 Mn |
| Mar 31, 2023 | 61.00 Mn |
| Mar 31, 2022 | 109.00 Mn |
| Mar 31, 2021 | 124.00 Mn |
| Mar 31, 2020 | 59.00 Mn |
| Mar 31, 2019 | 369.00 Mn |
| Mar 31, 2018 | 452.00 Mn |
| Dec 31, 2009 | 219.00 Mn |
| Sep 30, 2009 | 270.00 Mn |
| Jun 30, 2009 | 291.00 Mn |